(Q44910338)

7 December 2017

title

Elevations in serum creatinine concentration: concerning or reassuring? (English)

1 reference

7 December 2017

Benjamin J Epstein

1

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

24

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

697-702; discussion 702-3

1 reference

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

The underutilization of cardiac medications of proven benefit, 1990 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Microalbuminuria as predictor of increased mortality in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Acute Renal Failure Secondary to Angiotensin II Receptor Blockade in a Patient with Bilateral Renal Artery Stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Angiotensin II as a mediator of tubulointerstitial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

21 January 2018

Renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.697.34731

10.1592/PHCO.24.6.697.34731

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference